U 89678

Known as: U-89678 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1998
1998
Tirilazad mesylate (FREEDOX), a potent inhibitor of membrane lipid peroxidation in vitro, is under clinical development for the… (More)
  • figure 1
  • figure 3
  • figure 2
  • figure 4
  • table 1
Is this relevant?
1998
1998
The effect of oral finasteride, an inhibitor of 5alpha-reductase, on the clearance of tirilazad, a membrane lipid peroxidation… (More)
  • figure 1
  • figure 2
  • table 1
  • table 2
  • figure 3
Is this relevant?
1997
1997
The pharmacokinetics of tirilazad and U-89678 (an active metabolite) were evaluated in 55 adults (48 males, 7 females) with… (More)
Is this relevant?
1997
1997
The dose proportionality of tirilazad pharmacokinetics at dosages above 6.0 mg/kg/day were assessed in 18 healthy male volunteers… (More)
Is this relevant?
1996
1996
The 21-aminosteroid lipid-peroxidation inhibitor, tirilazad mesylate (U-74006F), recently was shown in a large multinational… (More)
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
1996
1996
Objective: Tirilazad mesylate is a membrane lipid peroxidation inhibitor being evaluated for the treatment of patients with… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
Is this relevant?
1996
1996
The pharmacokinetics of tirilazad mesylate and its active reduced metabolite, U-89678, were evaluated in ischemic stroke patients… (More)
Is this relevant?
1995
1995
The pharmacokinetics of tirilazad were assessed in men ages 40--60 years, women <40 years of age, premenopausal women ages 40--60… (More)
Is this relevant?
1994
1994
Multiple dose pharmacokinetics and tolerability of tirilazad mesylate were assessed at the maximum dosage and duration expected… (More)
Is this relevant?
1994
1994
The pharmacokinetic interaction between phenytoin and tirilazad was studied in 12 healthy men who received 200 mg phenytoin… (More)
Is this relevant?